{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:59:55Z","timestamp":1792814395983,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Checkpoint inhibition induced immune-related adverse events (irAE) may be steroid-dependent or steroid-refractory and are associated with increased morbidity, mortality and potentially compromised anti-tumor immunity. Extracorporeal photopheresis (ECP) has emerged as an alternative for salvage therapy, however, evidence remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This monocenter retrospective study included patients with either irColitis or irHepatitis, who received ECP after failure or dependence on high-dose corticosteroids + infliximab\/vedolizumab or mycophenolate mofetil\/tacrolimus. Clinical activity was quantified at least weekly (stool frequency for colitis; AST\/ALT for hepatitis) and primary endpoint was change in irAE activity over time. Secondary analyses included steroid-sparing, overall safety, and melanoma-specific outcomes. Spearman\u2019s correlation assessed irAE severity reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six patients were included in this study (irColitis n = 4; irHepatitis n = 2; CTCAE \u2265 3). Extracorporeal photopheresis was started after initial therapy with corticosteroids and immunosuppression was not successful. All ECP cycles included two consecutive treatment days. irAE activity declined promptly after ECP across patients: irColitis showed strong negative correlation with time since ECP (r\n                      <jats:sub>s<\/jats:sub>\n                      range -0.88 to -0.97); irHepatitis displayed parallel ALT\/AST declines (r\n                      <jats:sub>s<\/jats:sub>\n                      \u2265 -0.92). Corticosteroids were tapered following ECP start with a median corticosteroid reduction across all patients to 25% of baseline dose (IQR: 20.7 - 33.3) by week 4 and to &amp;lt;5% of baseline dose by week 9 (IQR: 1.6 - 4.7). No ECP-related adverse events were observed. Accelerated disease progression was not observed during or after ECP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>This study of six patients with irColitis or irHepatitis provides evidence that use of ECP is associated with clinical remission and steroid sparing, while demonstrating an excellent safety profile and not compromising disease control. Our data supports the use of ECP as salvage therapy for steroid- and immunosuppression- refractory irAE in cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1727312","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T06:28:32Z","timestamp":1765866512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Carl Maximilian","family":"Thielmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Andrea","family":"Seier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Jessica","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Dissemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sondermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Krefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpaslan","family":"Tasdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Roesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rambow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Malte","family":"Placke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e201611","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086006","article-title":"Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers","volume":"14","author":"Bojanic","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"115049","DOI":"10.1016\/j.ejca.2024.115049","article-title":"Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study","volume":"212","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000510","article-title":"Extracorporeal photopheresis as a treatment option for immune-related adverse events: two case reports and a prospective study","volume":"47","author":"Ruf","year":"2024","journal-title":"J Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18780","article-title":"Successful treatment of PD-1 inhibitor-induced psoriasis with infliximab","volume":"37","author":"Hansen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.09.009","article-title":"Immune-mediated colitis after immune checkpoint inhibitor therapy","volume":"31","author":"Giesler","year":"2025","journal-title":"Trends Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"113313","DOI":"10.1016\/j.ejca.2023.113313","article-title":"Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology","volume":"193","author":"Alouani","year":"2023","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jgh3.12868","article-title":"Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study","volume":"7","author":"Kadokawa","year":"2023","journal-title":"JGH Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) -A tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1727312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T06:28:33Z","timestamp":1765866513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1727312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1727312"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1727312","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"article-number":"1727312"}}